Back to Journals » Virus Adaptation and Treatment » Volume 2

Resistance patterns and genetic variations in patients with hepatitis C virus: emerging role of telaprevir

Authors C Argentini, D Genovese, S Catone

Published 9 June 2010 Volume 2010:2 Pages 59—62

DOI https://doi.org/10.2147/VAAT.S7209

Review by Single-blind

Peer reviewer comments 2

C Argentini, D Genovese, S Catone

Istituto Superiore di Sanità, Department of Therapeutic Research and Medicine Evaluation, Rome, Italy

Abstract: High genetic variability is a characteristic of hepatitis C virus (HCV) infection: infinite virus isolates are classified into six genotypes plus an emerging seventh one, and an indefinite number of subtypes. The variability is directly connected to the environmental adaptation of infective agents or to the change induced by antiviral therapies. During therapy, wild type isolates are substituted by resistant mutants that are able to maintain the infection. The standard therapy (pegylated interferon [PEG-IFN] and ribavirin) only partially eradicates HCV infection. However, particularly in genotype 1 infection, the rate of uncured patients remains high (between 50% and 60%). Specifically targeted antiviral therapies for HCV infection (STAT-C) consist of developing new antivirals aimed at blocking the virus proteins involved in different replication steps. Telaprevir is an anti-NS3-NS4 protease in phase III trials and represents a promising therapy, especially when associated with PEG-IFN and ribavirin. In vitro and in vivo research studies describe mutations that confers resistance to telaprevir in NS3-NS4 protease (V36A/M/L/G, F43, T54A, R130K, R155L/K/T/Q, A156T/S/V, V170A and Q195K). The emergence of these mutations describes the adaptation capability of HCV infection.
Keywords: HCV, telaprevir, resistance, antiviral therapy, virus adaptation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010